Auto Amazon Links: No products found. Blocked by captcha.
The NHS in England will begin rolling out a weight-loss drug called Mounjaro to patients starting in March 2022, according to final draft guidance from the National Institute for Health and Care Excellence (NICE). The drug, made by Eli Lilly, makes patients feel fuller so that they eat less. It will be offered to obese individuals with a body mass index (BMI) of over 35 and at least one obesity-related health problem, potentially reaching 3.4 million people.
However, concerns over how the drug could overwhelm available services, particularly general practitioners (GPs), has led to a decision to give the NHS an unprecedented decade-long period to gradually introduce it. Only patients under the care of specialist weight-management services will be offered the drug to start with. However, from June, the NHS will begin offering the drug to others, although it is unclear how this will be done, and questions remain about who will monitor progress and provide ongoing support involving diet and exercise.
Patient groups have expressed disappointment at the lengthy rollout period. Still, NICE Chief Medical Officer Prof Jonathan Benger defended the move, saying, “We’ve had to make this difficult decision in order to test ways of delivering this new generation of weight-loss medications.”
The drug, which is given via weekly injections, costs £122 per patient per month and is expected to benefit an estimated 250,000 patients in the first three years. Patients must have one obesity-related condition such as heart disease, high blood pressure, or diabetes to be eligible for treatment. Mounjaro is part of a new generation of weight-loss drugs that make it easier for health professionals to treat severe obesity
Read the full article from The BBC here: Read More
Auto Amazon Links: No products found. Blocked by captcha.